Nature Communications (Mar 2022)

Inhibition of lung microbiota-derived proapoptotic peptides ameliorates acute exacerbation of pulmonary fibrosis

  • Corina N. D’Alessandro-Gabazza,
  • Taro Yasuma,
  • Tetsu Kobayashi,
  • Masaaki Toda,
  • Ahmed M. Abdel-Hamid,
  • Hajime Fujimoto,
  • Osamu Hataji,
  • Hiroki Nakahara,
  • Atsuro Takeshita,
  • Kota Nishihama,
  • Tomohito Okano,
  • Haruko Saiki,
  • Yuko Okano,
  • Atsushi Tomaru,
  • Valeria Fridman D’Alessandro,
  • Miyako Shiraishi,
  • Akira Mizoguchi,
  • Ryoichi Ono,
  • Junpei Ohtsuka,
  • Masayuki Fukumura,
  • Tetsuya Nosaka,
  • Xuenan Mi,
  • Diwakar Shukla,
  • Kensuke Kataoka,
  • Yasuhiro Kondoh,
  • Masaki Hirose,
  • Toru Arai,
  • Yoshikazu Inoue,
  • Yutaka Yano,
  • Roderick I. Mackie,
  • Isaac Cann,
  • Esteban C. Gabazza

DOI
https://doi.org/10.1038/s41467-022-29064-3
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 23

Abstract

Read online

Here, the authors show that treatment with a monoclonal neutralizing antibody against the lung microbiota-derived proapoptotic peptide corisin ameliorates acute exacerbation of pulmonary fibrosis and severity of endotoxin-induced acute lung injury in mice.